WO2004000043A2 - Nutraceutic compositions and food supplements containing nadh - Google Patents
Nutraceutic compositions and food supplements containing nadh Download PDFInfo
- Publication number
- WO2004000043A2 WO2004000043A2 PCT/EP2003/006256 EP0306256W WO2004000043A2 WO 2004000043 A2 WO2004000043 A2 WO 2004000043A2 EP 0306256 W EP0306256 W EP 0306256W WO 2004000043 A2 WO2004000043 A2 WO 2004000043A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nadh
- compositions
- atp
- lycopene
- zinc
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 6
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims abstract description 29
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims abstract description 29
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 15
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims abstract description 15
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 15
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 15
- 235000012661 lycopene Nutrition 0.000 claims abstract description 15
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims abstract description 15
- 229960004999 lycopene Drugs 0.000 claims abstract description 15
- 239000001751 lycopene Substances 0.000 claims abstract description 15
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 15
- 229940016667 resveratrol Drugs 0.000 claims abstract description 15
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims abstract description 15
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 9
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 26
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 18
- 235000016804 zinc Nutrition 0.000 claims description 13
- 239000011701 zinc Substances 0.000 claims description 13
- 229910052725 zinc Inorganic materials 0.000 claims description 13
- 239000004208 shellac Substances 0.000 claims description 8
- 235000013874 shellac Nutrition 0.000 claims description 8
- 229920001800 Shellac Polymers 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 7
- 229940113147 shellac Drugs 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims 3
- 239000013589 supplement Substances 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000004936 stimulating effect Effects 0.000 abstract description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 17
- 238000009472 formulation Methods 0.000 description 6
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 5
- 229950006238 nadide Drugs 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229960002666 1-octacosanol Drugs 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- IYWFOPPYQUEKHN-UHFFFAOYSA-N 5-(2-phenylethenyl)benzene-1,2,3-triol Chemical compound OC1=C(O)C(O)=CC(C=CC=2C=CC=CC=2)=C1 IYWFOPPYQUEKHN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- LHQIJBMDNUYRAM-AWFVSMACSA-N D-erythro-biopterin Chemical compound N1=C(N)NC(=O)C2=NC([C@H](O)[C@H](O)C)=CN=C21 LHQIJBMDNUYRAM-AWFVSMACSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- LHQIJBMDNUYRAM-UHFFFAOYSA-N L-erythro-Biopterin Natural products N1=C(N)NC(=O)C2=NC(C(O)C(O)C)=CN=C21 LHQIJBMDNUYRAM-UHFFFAOYSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100436871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) atp-3 gene Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 244000172730 Rubus fruticosus Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000001343 mnemonic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention refers to nutraceutic compositions and food supplements comprising NADH, ATP and antioxidants, in particular resveratrol and lycopene.
- the compositions according to the invention are capable of stimulating the physiological production of energy (pro-energetic and anti-asthenic activity).
- Nicotinamide adenine dinucelotide (NAD) in its reduced form (NADH) is a physiological substance which is found in all living cells; NAD is also defined as coenzyme I, as it is cofactor of several enzymes, which catalyze oxidoreduction reactions.
- NAD coupled to dehydrogenase, oxidizes biological media by accepting hydrogen and it is then re-oxidized by flavoproteins.
- NADH The most important role of NADH is the energy production through a mitochondrial process, the "oxidative phosphorylation", in which 3 ATP molecules are formed for every single NADH molecule and half oxygen molecule.
- NADH is formed from glycolysis metabolites (lactate and pyruvate) and is carried into the mitochondrion thanks to two "shuttle” systems, glycerol phosphate and malate - aspartate.
- NADH a tyrosine hydroxylase cofactor, the enzyme which converts L-Dopa in dopamine; further NADH has a direct stimulation action of tyrosine hydroxylase activity.
- NADH also stimulates the endogenous adrenaline and noradrenaline bio-synthesis, thus it is effective in the therapy of depression (Birkmayer, J.G.D., Birkmayer W. New Trends in Clinical Neuropharmacology, Vol. 5 - n. 3 / 4 - 1991).
- NADH is essential to poly (ADP-ribose) polymerase enzyme, its administration prevents DNA breaking processes and it inhibits stress oxidative phenomena (Adams et al. Annali New York Academy of Sciences, 1996, 786-135-131) and thanks to its anti-oxidative action, it may regenerate other important antioxidants thus protecting from damages caused by free radicals.
- NADH is unstable to the pH of gastric juices, it may be orally administered only in gastro-protected form, preferably associated with vitamin E, sodium bicarbonate, ascorbic acid, sodium ascorbate, as disclosed in US 5,332,727 and in US 5,712,259.
- Adenosine triphosphate is the coenzyme which is found in high concentration in mammal muscles, and it is required for high energy phosphates bonds.
- the conversion of ATP in ADP (adenosine diphosphate) provides the energy required for most physiological processes of the organism.
- exogenous ATP restores physiological ATP levels in myosin fibers, when they are lowered below a certain threshold (Chaudry IH, Yale J. Biol. Med. 1982; 55:1-10).
- ATP oral pharmaceutical compositions have already been suggested for muscular and cerebral fatigue treatment.
- Lycopene is a carotenoid, which is contained in high quantities in tomato skins and is characterized by high anti-oxidative properties. As it can be seen from more and more clinical studies, lycopene involves a series of advantages for health and, in particular, it provides valid protection against several epithelial tumours and cardiovascular diseases and it delayes body cells ageing.
- Resveratrol (3,4,5-trihydroxystilbene) is a polyphenol to which anti- tumoural, anti-oxidant, anti-inflammatory and anti-thrombotic properties are ascribed. In particular, it has been shown that resveratrol modulates lipid metabolism and inhibits low-density lipoproteins LDL oxidation and platelets aggregation through copper capture. It is found in grapefruits, raisins, blackberries, peanuts, but especially in grape skin and in particular in red wine.
- Zinc acts as regulator of enzymatic systems. Recent studies underline its fundamental role in cerebral functions and treatment of schizophrenia. Further, it improves reflex and mental quickness. DESCRIPTION OF THE INVENTION
- the association of NADH, adenosine triphosphate (ATP) and antioxidants, in particular resveratrol, lycopene and optionally zinc is particularly advantageous, thanks to proenergetic synergistic effects between NADH and ATP and to the enhancement of the antioxidant/antiradical effect obtainable through the association of lycopene, resveratrol and zinc.
- the present invention provides nutraceutic compositions and food supplements comprising NADH, ATP and antioxidants, preferably resveratrol and lycopene, and optionally zinc, useful for stimulating the organism to produce energy in physical fatigue states, while practicing sports and/or anyhow under all circumstances where energy consumption is expected and in the conditions under which the administering of NADH brings advantages.
- compositions according to the invention preferably have the following percentage composition (by weight on the total composition):
- Zinc will preferably be in the form of salts with organic acids, in particular lactate.
- compositions according to the invention may be administered with the addition of suitable excipients, in form of hard capsules, soft capsules and tablets.
- Tablets with gastroenteral coating which can be accomplished by conventional methods and excipients, are preferred.
- Shellac Rubber a natural polymer, is applied on tablets by spraying in aqueous solution, further containing one or more plasticizing agents (glycerine, lauric acid, oleic acid, polyvinyl pyrrolidone in an amount comprised in the range from 0.5 to 4%, one or more anti-adhesive agents (talcum, silicon dioxide / colloidal silica), in an amount comprised in the range from 2 to 8%, and optionally one or more dye or opacifying agents.
- plasticizing agents glycol, lauric acid, oleic acid, polyvinyl pyrrolidone
- anti-adhesive agents talcum, silicon dioxide / colloidal silica
- Shellac Rubber is used for tablet gastro-protection in an amount ranging from 2 to 8% by weight of the tablet itself.
- the coating process occurs preferably through a rotating coating pan, at a temperature not above 34-35°C.
- a cooling step is carried out at the end of the drying process.
- a fluidized bed granulator-coater apparatus in which the solution to be applied is sprayed from one or more nozzles on the tablet mass kept in motion in a basket (or granulator bucket) by an air stream, which dries the tablets themselves at the same time, can be used as alternative to the rotating coating pan.
- the tablets thus coated should be kept intact for at least 30 minutes in an aqueous solution at a pH of 1.5 at 37°C.
- the formulations according to the invention preferably contain for each unitary dose from 1 to 10 mg NADH, preferably from 2 to 5 mg; from 1 to 10 mg resveratrol, preferably from 2 to 5 mg; from 1 to 10 mg lycopene, preferably from 2 to 5 mg; from 1 to 5 mg ATP, preferably from 2 to 4 mg; from 10 to 20 mg zinc, preferably from 15 to 17 mg.
- compositions according to the invention administered once or twice a day, produce advantageous effects when a restoration of the energy store in fatigued, immuno-depressed organisms and in organisms, which underwent physiological disequilibria induced by the development of free radicals, is convenient.
- the compositions according to the invention are particularly suitable for persons undertaking intensive trainings, for cognitive and mnemonic skills and in the treatment or prevention of depressions, fatigue, stress and in the ageing processes.
- Example 1 formulation for 300 mg tablet
- Example 2 formulation for 300 mg tablet
- Example 3 formulation for 300 mg tablet
- Example 4 formulation for 300 mg tablet
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03760616A EP1531690A2 (en) | 2002-06-21 | 2003-06-13 | Nutraceutic compositions and food supplements containing nadh |
AU2003246430A AU2003246430A1 (en) | 2002-06-21 | 2003-06-13 | Nutraceutic compositions and food supplements containing nadh |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2002A001366 | 2002-06-21 | ||
IT2002MI001366A ITMI20021366A1 (en) | 2002-06-21 | 2002-06-21 | NUTRACEUTICAL COMPOSITIONS AND FOOD SUPPLEMENTS CONTAINING NADH |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004000043A2 true WO2004000043A2 (en) | 2003-12-31 |
WO2004000043A3 WO2004000043A3 (en) | 2004-03-04 |
Family
ID=11450057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/006256 WO2004000043A2 (en) | 2002-06-21 | 2003-06-13 | Nutraceutic compositions and food supplements containing nadh |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1531690A2 (en) |
AU (1) | AU2003246430A1 (en) |
IT (1) | ITMI20021366A1 (en) |
WO (1) | WO2004000043A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010132024A1 (en) * | 2009-05-14 | 2010-11-18 | Hsiehs Biotech (Singapore) Pte Ltd | Lycopene and resveratrol compositions for nk cell activation resulting in anti-neoplastic effect |
WO2010132021A1 (en) | 2009-05-14 | 2010-11-18 | Hsiehs Biotech (Singapore) Pte Ltd | Lycopene and resveratrol dietary supplement |
WO2018148930A1 (en) * | 2017-02-17 | 2018-08-23 | 纯菁生物科技(美国)有限公司 | Use of nadh or fadh2 in nutritional intervention for cancer patient |
CN115299534A (en) * | 2022-09-14 | 2022-11-08 | 泓博元生命科技(深圳)有限公司 | NADH composition for quickly supplementing energy and relieving fatigue of pets and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5712259A (en) * | 1996-04-22 | 1998-01-27 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome |
WO1999001148A1 (en) * | 1997-07-02 | 1999-01-14 | Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.P.A. | Pharmaceutical composition containing polyphenols from grapes, in particular resveratrol, and yeast extracts |
EP1161884A1 (en) * | 2000-06-09 | 2001-12-12 | World Pharma Tech Ltd. | Proenergetic food supplement based on NADH, Octacosanol and Vitamin E |
WO2002064129A2 (en) * | 2001-02-14 | 2002-08-22 | Rath, Matthias | Compositions of biochemical compounds involved in bioenergy metabolism of cells |
-
2002
- 2002-06-21 IT IT2002MI001366A patent/ITMI20021366A1/en unknown
-
2003
- 2003-06-13 AU AU2003246430A patent/AU2003246430A1/en not_active Abandoned
- 2003-06-13 EP EP03760616A patent/EP1531690A2/en not_active Withdrawn
- 2003-06-13 WO PCT/EP2003/006256 patent/WO2004000043A2/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5712259A (en) * | 1996-04-22 | 1998-01-27 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome |
WO1999001148A1 (en) * | 1997-07-02 | 1999-01-14 | Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.P.A. | Pharmaceutical composition containing polyphenols from grapes, in particular resveratrol, and yeast extracts |
EP1161884A1 (en) * | 2000-06-09 | 2001-12-12 | World Pharma Tech Ltd. | Proenergetic food supplement based on NADH, Octacosanol and Vitamin E |
WO2002064129A2 (en) * | 2001-02-14 | 2002-08-22 | Rath, Matthias | Compositions of biochemical compounds involved in bioenergy metabolism of cells |
Non-Patent Citations (1)
Title |
---|
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995 MAURICIO J C ET AL: "Changes in the intracellular concentrations of the adenosine phosphates and nicotinamide adenine dinucleotides of Saccharomyces cerevisiae during batch fermentation" Database accession no. PREV199598233952 XP002264594 & WORLD JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, vol. 11, no. 2, 1995, pages 196-201, ISSN: 0959-3993 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010132024A1 (en) * | 2009-05-14 | 2010-11-18 | Hsiehs Biotech (Singapore) Pte Ltd | Lycopene and resveratrol compositions for nk cell activation resulting in anti-neoplastic effect |
WO2010132021A1 (en) | 2009-05-14 | 2010-11-18 | Hsiehs Biotech (Singapore) Pte Ltd | Lycopene and resveratrol dietary supplement |
US20120121699A1 (en) * | 2009-05-14 | 2012-05-17 | Hsiehs Biotech (Singapore) Pte Ltd | Lycopene and resveratrol dietary supplement |
CN102481267A (en) * | 2009-05-14 | 2012-05-30 | 谢氏生技(新加坡)有限公司 | Lycopene and resveratrol compositions for nk cell activation resulting in anti-neoplastic effect |
JP2012526807A (en) * | 2009-05-14 | 2012-11-01 | シェーズ バイオテック(シンガポール)プライベート リミテッド | Composition comprising lycopene and resveratrol for NK cell activation resulting in antitumor activity |
US20150132373A1 (en) * | 2009-05-14 | 2015-05-14 | Hsiehs Biotech (Singapore) Pte Ltd | Lycopene and resveratrol dietary supplement |
US9610255B2 (en) * | 2009-05-14 | 2017-04-04 | Hsiehs Biotech (Singapore) Pte Ltd | Lycopene and resveratrol dietary supplement |
WO2018148930A1 (en) * | 2017-02-17 | 2018-08-23 | 纯菁生物科技(美国)有限公司 | Use of nadh or fadh2 in nutritional intervention for cancer patient |
CN115299534A (en) * | 2022-09-14 | 2022-11-08 | 泓博元生命科技(深圳)有限公司 | NADH composition for quickly supplementing energy and relieving fatigue of pets and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
ITMI20021366A1 (en) | 2003-12-22 |
ITMI20021366A0 (en) | 2002-06-21 |
EP1531690A2 (en) | 2005-05-25 |
AU2003246430A8 (en) | 2004-01-06 |
AU2003246430A1 (en) | 2004-01-06 |
WO2004000043A3 (en) | 2004-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sharma et al. | A comprehensive review of free radicals, antioxidants, and their relationship with human ailments | |
US11331363B2 (en) | Phytocomplexes exhibiting multiple, synergistic antioxidant activities useful in foods, dietary supplements, cosmetics and pharmaceutical preparations | |
JP2022176979A (en) | CRYSTAL FORMS OF β-NICOTINAMIDE MONONUCLEOTIDE | |
EP3359259B1 (en) | Resetting biological pathways for defending against and repairing deterioration from human aging | |
JP6919099B2 (en) | VMAT2 inhibitors for treating neurological disorders or disorders | |
Qiao et al. | Antioxidant activities of polysaccharides from Hyriopsis cumingii | |
CN104997803B (en) | Comprising the treatment using magnetic dipole stabilizing solutions or improves disease and enhance the method and composition of performance | |
Roberts et al. | Vitamin C consumption does not impair training-induced improvements in exercise performance | |
US20090104171A1 (en) | Metabolic Enhancement Therapy | |
Lin et al. | Protective effect of green tea (-)-epigallocatechin-3-gallate against the monoamine oxidase B enzyme activity increase in adult rat brains | |
CN107847513B (en) | Composition for preventing and treating obesity or impaired glucose tolerance comprising nicotinamide adenine dinucleotide | |
Arenas-Jal et al. | Therapeutic potential of nicotinamide adenine dinucleotide (NAD) | |
ITMI20001285A1 (en) | PROENERGETIC FOOD SUPPLEMENT BASED ON NADH OCTOCOSANOL AND VITAMIN E | |
Wang et al. | Nicotinamide mononucleotide administration after sever hypoglycemia improves neuronal survival and cognitive function in rats | |
RU2270008C1 (en) | Agent and method for enhancing human and animal resistance to hypothermia by activation of vital essential biochemical processes | |
WO2004000043A2 (en) | Nutraceutic compositions and food supplements containing nadh | |
Sudheesh et al. | Palladium α-lipoic acid complex formulation enhances activities of Krebs cycle dehydrogenases and respiratory complexes I–IV in the heart of aged rats | |
CA3145853A1 (en) | Compositions and methods using trigonelline to produce intracellular nicotinamide adenine dinucleotide (nad+) for treating or preventing physiological disorders or states | |
WO2016027837A1 (en) | Oral beauty care agent | |
JP6824746B2 (en) | Antioxidants and Antioxidants / UV Care Cosmetics | |
CN113615833A (en) | Mitochondrial nutrient composition for improving cardiovascular disease and application thereof | |
WO2011091299A1 (en) | Composition for perinatal and neonatal stroke | |
CA3157712C (en) | Synergistic nutritional compositions for enhancing atp efficiency | |
WO2012080952A1 (en) | Composition containing resveratrol, l-tryptophan, l-aspartic acid and vitamin b3 for use in the pharmaceutical, nutritional and cosmetic fields | |
Pawlas et al. | Neuroprotective effect of N-acetylcysteine in neurons exposed to arachidonic acid during simulated ischemia in vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003760616 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003760616 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003760616 Country of ref document: EP |